A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours

BB-3644 is an oral, broad-spectrum matrix metalloproteinase inhibitor (MMPI) structurally related to marimastat and BB-94. It is also >10-fold more active than marimastat in inhibiting the processing of cell-bound TNF-α. Preclinical studies suggested a favourable toxicity profile when compared to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wall, L, Talbot, D C, Bradbury, P, Jodrell, D I
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410175/
https://www.ncbi.nlm.nih.gov/pubmed/14970856
http://dx.doi.org/10.1038/sj.bjc.6601594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410175/
https://www.ncbi.nlm.nih.gov/pubmed/14970856
http://dx.doi.org/10.1038/sj.bjc.6601594

Ejemplares similares